Small Stocks, Big Money™

OS Therapies (NYSE American: OSTX) established a Scientific and Medical Advisory Board (SMAB) featuring leading experts in osteosarcoma from top U.S. institutions. The SMAB will advise on the development of OST-HER2, the company's innovative immunotherapy for osteosarcoma, as it advances toward a potential Biologics License Authorization (BLA). With a fully enrolled Phase IIb trial and promising interim data, OS Therapies aims for Breakthrough Therapy Designation, with topline results expected in Q4 2024. OST-HER2 has received multiple regulatory designations, positioning it as a potential game-changer in osteosarcoma treatment.

Unusual Machines (NYSE American: UMAC) achieved a significant milestone with its Rotor Riot Brave F7 Flight Controller being approved for the Blue UAS Framework, a key certification by the Defense Innovation Unit (DIU). This approval highlights the company's commitment to delivering secure, domestically manufactured drone components for U.S. government and critical sectors. As the first U.S.-made FPV flight controller on the Blue UAS list, this development positions Unusual Machines as a crucial player in the growing $115 billion U.S. drone industry.

LOBO EV Technologies (Nasdaq: LOBO) bolstered its manufacturing capabilities with the addition of a new 107,639-square-foot facility in the Wuqing Development Zone, China. This expansion, driven by increasing global demand for electric mobility solutions, will primarily focus on producing e-tricycles, easing the load on existing operations. CEO Huajian Xu emphasized that this strategic move enhances production efficiency and positions LOBO to meet growing market needs. With the e-mobility market expected to surpass $39 billion by 2028, LOBO is well-prepared to capitalize on the sector's rapid growth.

Soligenix, (Nasdaq: SNGX) announced its Q2 2024 financial results alongside significant recent accomplishments. The company is gearing up for a confirmatory Phase 3 trial of HyBryte™ for early-stage cutaneous T-cell lymphoma (CTCL) following positive results from a comparability study showing superior efficacy and safety compared to Valchlor®. Additionally, a Phase 2 study of SGX945 for Behçet's disease is set to begin later this year. Soligenix reported a net loss of $1.6 million for the quarter, with $9.1 million in cash as of June 30, 2024, bolstered by recent warrant exercises.